Abstract
Background/Aims: In this crossover study, we investigated whether nizatidine, a H2-receptor antagonist, can alleviate clinical symptoms and gastric emptying in patients with Rome III-based functional dyspepsia (FD) with or without impaired gastric emptying. Methods: We enrolled 30 patients presenting with FD symptoms (epigastric pain syndrome, n = 6; postprandial distress syndrome, n = 24). Rome III-based FD patients were treated with nizatidine (300 mg/day) or placebo for 4 weeks in a crossover trial. Gastric motility was mainly evaluated with the Tmax value using the 13C-acetate breath test. Meal-related symptoms were defined as postprandial fullness and early satiation. Gastroesophageal symptom was defined as a burning feeling rising from the stomach or lower chest up toward the neck. Acylated- and desacylated ghrelin levels were evaluated by the ELISA method. Clinical symptoms, gastric emptying and ghrelin levels were evaluated at three different points during the study (pretreatment, after 4 weeks former treatment and after 4 weeks later treatment). The primary end point of this study was to determine whether nizatidine would improve clinical symptoms and gastric emptying in FD patients with or without impaired gastric emptying via affecting ghrelin levels. Results: Meal-related symptoms of the patients treated with nizatidine improved significantly (21/30; 70%) compared to those treated with placebo (3/30; 10%). In addition, nizatidine treatment also significantly improved gastroesophageal symptoms (16/30; 53%) compared to those treated with placebo (0/30; 0%). Nizatidine treatment in patients with FD accompanied by impaired gastric emptying significantly improved clinical symptoms and Tmax value as a marker of gastric emptying (10/11, 91%; 9/11, 82%) compared to placebo therapy, respectively. There were no significant differences in ghrelin levels between nizatidine treatment and placebo therapy. Conclusion: Nizatidine administration significantly improved both gastric emptying and clinical symptoms in FD patients with impaired gastric emptying.
Journal Section:
Original Paper
References
1.
Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377–1390.
[PubMed]
2.
Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd: Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259–1268.
[PubMed]
3.
Castillo EJ, Camilleri M, Locke GR, Burton DD, Stephens DA, Geno DM, Zinsmeister AR: A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2004;2:985–996.
[PubMed]
4.
Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998;115:1346–1352.
[PubMed]
5.
Lunding JA, Tefera S, Gilja OH, Hausken T, Bayati A, Rydholm H, Mattsson H, Berstad A: Rapid initial gastric emptying and hypersensitivity to gastric filling in functional dyspepsia: effects of duodenal lipids. Scand J Gastroenterol 2006;41:1028–1036.
[PubMed]
6.
Holtmann G, Goebell H, Talley J: Impaired small intestinal peristalistic refluxes and sensory thresholds are independent functional disturbances in patients with chronic unexplained dyspepsia. Am J Gastroenterol 1996;91:485–491.
[PubMed]
7.
Samsom M, Verhagen MA, van Berge Henegouwen GP, Smout AJ: Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999;116:515–520.
[PubMed]
8.
Takahashi Y, Amano Y, Yuki T, Ose T, Miyake T, Kushiyama Y, Sato S, Ishihara S, Kinoshita Y: Influence of acid suppressants on gastric emptying: cross-over analysis in healthy volunteers. J Gastroenterol Hepatol 2006;21:1664–1668.
[PubMed]
9.
Quigley EM: Gastric motor and sensory function, and motor disorders of the stomach; in Feldman M, Friedman LS, Sleisenger MH (eds): Gastrointestinal and liver Disease, Pathophysiology/Diagnosis/Management. Philadelphia, WB Saunders, 2002, pp 691–714.
10.
Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R: Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17:537–545.
[PubMed]
11.
Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R: Effectiveness of proton pump inhibitors in non-erosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656–664.
[PubMed]
12.
Futagami S, Iwakiri K, Shindo T, Kawagoe T, Horie A, Shimpuku M, Tanaka Y, Kawami N, Gudis K, Sakamoto C: The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol 2010;45:413–421.
13.
Thomson AB, Sauve MD, Kassam N, Kamitakahara H: Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010;16:2323–2330.
14.
Valuck RJ, Ruscin JM: A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004;57:422–428.
15.
Leonard J, Marshall JK, Moayyedi P: Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047–2056.
[PubMed]
16.
Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J: Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Internal Med 2007;167:950–955.
[PubMed]
17.
Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947–2953.
[PubMed]
18.
Harasawa S, Miwa T: The effect of nizatidine on gastric emptying and plasma gastrin concentration in patients with peptic ulcer. Jpn Pharmacol Ther 1993;21:971–975.
19.
Tomokane Y, Nomura M, Kujime S, Noda Y, Kondo N, Nakaya Y, Ito S: Clinical study on the effects of nizatidine on gastric motility and cardiac autonomic function. Investigations using electrogastrography and spectral analysis of heart rate variability. Arzneimittelforschung 2004;54:427–435.
20.
Cooke AR: Duodenal acidification: role of the first part of duodenum in gastric emptying and secretion in dogs. Gastroenterology 1974;67:85–92.
21.
Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V: Functional gastroduodenal disorders. Gastroenterology 2006;130:1466–1479.
[PubMed]
22.
McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, Kelman A, Penny C, Knill-Jones R, Hilditch T: Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869–1874.
[PubMed]
23.
Portincasa P, Altomare DF, Moschetta A, Baldassarre G, Di Ciaula A, Venneman NG, Rinaldi M, Vendemiale G, Memeo V, van Berge-Henegouwen GP, Palasciano G: The effect of acute oral erythromycin on gallbladder motility and on upper gastrointestinal symptoms in gastrectomized patients with and without gallstones: a randomized, placebo-controlled ultrasonographic study. Am J Gastroenterol 2000;95:3444–3451.
24.
Shimpuku M, Futagami S, Kawagoe T, Nagoya H, Shindo T, Horie A, Kodaka Y, Itoh T, Sakamoto C: G-protein β3 subunit 825CC genotype is associated with postprandial distress syndrome with impaired gastric emptying and with the feeling of hunger in Japanese. Neurogastroenterol Motil 2011;23:1073–1080.
25.
Rockliff BW: A brief self-rating questionnaire for depression (SRQ-D). Psychosomatics 1969;10:236–243.
26.
Hellmig S, Von Schoning F, Gadow C, Katsoulis S, Hedderich J, Folsh UR, Stuber E: Gastric emptying time of fluids and solids in healthy subjects determined by 13C breath tests: influence of age, sex and body mass index. J Gastroenterol Hepatol 2006;21:1832–1838.
[PubMed]
27.
Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G: Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993;104:1640–1647.
[PubMed]
28.
Nyren O, Adami HO, Bates S, Bergstrom R, Gustavsson S, Loof L, Nyberg A: Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Eng J Med 1986;314:339–343.
29.
Farup PG, Wetterhus S, Osnes M, Ulshagen K: Ranitidine effectively relieves symptoms in a subset of patients with functional dyspepsia. Scand J Gastroenterol 1997;32:755–759.
30.
Johannessen T, Fjosne U, Kleveland PM, Halvorsen T, Kristensen P, Loge I, Hafstad PE, Sandbakken P, Petersen H: Cimetidine responders in non-ulcer dyspepsia. Scand J Gastroenterol 1988;23:327–336.
31.
Ryder SD, O’Reilly S, Miller RJ, Ross J, Jacyna MR, Levi AJ: Long term acid suppressing treatment in general practice. BMJ 1994;308:827–830.
32.
Thors H, Sigurdsson H, Oddsson E, Thjodleifsson B: Survey of prescriptions for peptic ulcer drugs (ACT class AOB2) in Iceland. Scand J Gastroenterol 1994;29:988–994.
33.
Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J: Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003;98:783–788.
[PubMed]
34.
Takahashi Y, Amano Y, Yuki T, Ose T, Miyake T, Kushiyama Y, Sato S, Ishihara S, Kinoshita Y: Influence of acid suppressions on gastric emptying: cross-over analysis in healthy volunteers. J Gastroenterol Hepatol 2006;21:1664–1668.
[PubMed]
35.
Kaneko H, Mitsuma T, Uchida K, Nagai H, Harada M, Kotera H: Nizatidine accelerates gastric emptying of a solid meal in rats. Dig Dis Sci 1995;40:2043–2051.
36.
Koskenpato J, Punkkinen JM, Kairemo K, Farkkila M: Nizatidine and gastric emptying in functional dyspepsia. Dig Dis Sci 2008;53:352–357.
37.
Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hori Y, Morita H, Tagashira E, Itoh Z: Gastroprokientic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther 1993;264:152–157.
38.
McCallum RW, Zarling EJ, Goetsch AC, Griffin C, Sarosiek I, Hejazi RA, Doyle RT, Rotenberg K: Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease. Am J Med Sci 2010;340:259–263.
39.
Svedlund J, Sjodin I, Dotevall G: GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33;129–134.
[PubMed]
40.
Revicki DA, Wood M, Wiklund I, Crawley J: Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual life Res 1998;7:75–83.
41.
Talley NJ, Verlinden M, Jones M: Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia? Am J Gastroenterol 2001;96:1422–1428.
[PubMed]
42.
Scott AM, Kellow JE, Shuter B, Cowan H, Corbett AM, Riley JW, Lunzer MR, Eckstein RP, Hoschl R, Lam SK, et al: Intragastric distribution and gastric emptying of solids and liquids in functional dyspepsia. Lack of influence of symptom subgroups and H. pylori-associated gastritis. Dig Dis Sci 1993;38:2247–2254.
[PubMed]
43.
Broglio F, Gottero C, Van Koetsveld P, Prodam F, Destefanis S, Benso A, Gauna C, Hofland L, Arvat E, van der Lely AJ, Ghigo E: Acetylcholine regulates ghrelin secretion in humans. J Clin Endocrinol Metab 2004;89:2429–2433.
[PubMed]
44.
Lee KJ, Cha DY, Cheon SJ, Yeo M, Cho SW: Plasma ghrelin levels and their relationship with gastric emptying in patients with dysmotility-like functional dyspepsia. Digestion 2009;80:58–63.
[PubMed]
45.
Nishizawa T, Suzuki H, Nomoto Y, Masaoka T, Hosoda H, Mori M, Ohara T, Morishita T, Kangawa K, Hibi T: Enhanced plasma ghrelin levels in patients with functional dyspepsia. Aliment Pharmacol Ther 2006;24(suppl 4):104–110.
46.
Shindo T, Futagami S, Hiratsuka T, Horie A, Hamamoto T, Ueki N, Kusunoki M, Miyake K, Gudis K, Tsukui T, Iwakiri K, Sakamoto C: Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion 2009;79:65–72.
[PubMed]
47.
Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K: Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000;276:905–908.
[PubMed]
48.
Kitazawa T, De Smet B, Verbeke K, Depoortere I, Peeters TL: Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro. Gut 2005;54:1078–1084.
[PubMed]
49.
Suzuki H, Masaoka T, Hosoda H, Nomura S, Ohara T, Kangawa K, Ishii H, Hibi T: Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio-a possible novel and non-invasive marker for gastric atrophy. J Hepatogastroenterol 2004;51:1249–1254.
[PubMed]
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.
